Adamis Pharmaceuticals announces commercial partnership with Emerge Health for Symjepi in Australia and New Zealand.

Adamis Pharmaceuticals Corporation announced that it has entered into an exclusive distribution and commercialization agreement with Emerge Health Pty to register and commercialize Adamis� Symjepi (epinephrine) Injection products in Australia and New Zealand. Under the terms of the agreement, Adamis will provide technical support to Emerge during the registration process, which could take more than a year. If successful, Adamis will begin supplying product to Emerge. Emerge will be responsible for the full registration, reimbursement, sales, marketing and distribution of Symjepi in Australia and New Zealand (the �Territory�). Once commercially launched, Adamis and Emerge will equally share net profits (as defined in the agreement) generated from sales of Symjepi in the Territory. Based on its experience with the registration process in the Territory, Emerge does not anticipate that a commercial launch could occur before 2021. Adamis hopes that Emerge will find a ready market for Symjepi as Australia has among the highest allergy rates in the world. A study published in 2017 in the Journal of Allergy and Clinical Immunology indicates that, in Australia, 1 in 10 infants and 1 in 20 children aged 10-14 years have food allergies. High rates of allergies typically result in higher incidences of anaphylaxis, and Australian hospital admissions for anaphylaxis have increased five-fold in the last 20 years. According to the Murdoch Children�s Research Institute in Victoria, Australia has one of the highest rates of hospital admissions for anaphylaxis in the developed world.